Skip to content
Sachs Forum 2025 Slide Presentation
View Presentation
Strategic Partnering
News
Presentations
Contact Us
Strategic Partnering
News
Presentations
Contact Us
Invest now
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Strategic Partnering
News
Presentations
Contact Us
Disease Areas
Topical Scarring & Burns
Organ Fibrosis
Autoimmune Disorders
Wrinkles & Rhytids
Our Science
Kynurenic Acid MoA
Immune Cells Therapy
University of British Columbia
Products & Pipeline
Clinical Program NHP/OTC and Cosmetics
Rx Clinical Program
About Us
Our Mission
Leadership
Grants
Strategic Partnering
News
Presentations
Contact Us
First Patient Enrolled in BirchBioMed’s Study Investigating FS2 for the Treatment of Scars
022819-Birch-first-patient-florida-Final2
